Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
BodySpec has opened a retail DEXA scanning location in Oakland offering roughly 12-minute body composition scans for under $60, reporting fat mass, visceral fat, lean muscle and bone density. The company positions the service against the rapid uptake of GLP-1 receptor agonists, citing evidence that 25 to 40 percent of weight lost on these drugs can be lean tissue. Muscle and bone mass are established predictors of functional independence and mortality risk, yet have historically been measured only inside clinical settings.
A Censuswide survey of 1,000 UK dieters, commissioned by nutrition brand PortionIQ, found that 29% of those using GLP-1 medications for two years or more lacked confidence in their knowledge of essential nutrients, compared with 12% of those in their first month. Only 57% of long-term users believed they were meeting their nutrient needs, against 81% of new users. With appetite suppression reducing total intake, nutrient density and protein adequacy become determinants of whether weight loss preserves or erodes lean mass and metabolic function.
Jupiter Neurosciences has dosed the first patient in RESET, a 30-person Phase 2a trial of JOTROL, a micellar trans-resveratrol formulation, in Parkinson's disease. The study is powered for safety, tolerability and pharmacokinetics — including cerebrospinal fluid levels — with exploratory biomarkers covering energy metabolism and inflammation, not efficacy. The same announcement disclosed that the company has engaged an adviser to evaluate a sale, licensing or other strategic transaction.
John Beard, who led the WHO's World Report on Ageing and Health, argues that function — not diagnosis count — is the more accurate measure of how a person is aging. Intrinsic capacity assesses five domains: cognition, mobility, psychological resilience, sensory function and vitality, and can be tracked incrementally from midlife rather than waiting decades for disease endpoints. Cohort data from England and China indicate newer generations reach a higher functional peak rather than declining more slowly, suggesting interventions can raise the ceiling, not only slow the descent.
Mission Therapeutics has begun Phase 1b dosing of MTX325, an orally bioavailable, brain-penetrant USP30 inhibitor designed to restore mitophagy — the selective clearance of damaged mitochondria — in patients with mild to moderate idiopathic Parkinson's disease. The 36-participant trial across the UK, Europe and Australia will assess safety, tolerability, biomarkers and imaging, with proof-of-mechanism data expected in late 2027. Targeting mitochondrial quality control rather than dopaminergic symptom replacement places this program among the first clinical tests of a core aging mechanism in neurodegeneration.
Oxford Healthspan has released Primeadine GF Spermidine Powder, a mixable gluten-free formulation delivering 1 mg of whole-food spermidine per serving from broken cell wall chlorella, with nobiletin from Shikuwasa citrus peel and curcumin. Spermidine is studied for its role in autophagy, the cellular recycling process that declines with age. The powder format addresses adherence by allowing the dose to be added to food or beverages rather than taken as a tablet.
Elysium has introduced Balance, a formulation combining its NAD+ precursor product Basis with S-equol and ergothioneine, positioned for perimenopausal and menopausal symptom relief alongside longer-term postmenopausal health. The company reports that an open-label pilot of Basis showed a significant increase in the estradiol-to-estrone ratio with reductions in hot flashes, disrupted sleep and bloating; a larger randomized placebo-controlled trial is planned. The estradiol-to-estrone ratio is an emerging marker of reproductive aging, making it a measurable target rather than a symptom-only endpoint.
In the REMAIN-1 pivotal cohort (N=308), a single endoscopic duodenal mucosal resurfacing procedure limited weight regain after tirzepatide discontinuation, with participants retaining roughly 80% of their drug-induced weight loss at six months versus 67% for sham. Mean regain was 5.1% versus 8.2%, and post hoc analysis indicated a dose-dependent effect, with ablation lengths of 20 cm or greater associated with 3.8% regain. The approach targets the durability problem that currently limits incretin-based weight loss as a long-term metabolic strategy.
Renue by Science has opened a decentralized research platform allowing adults to enroll in Institutional Review Board-reviewed studies from home, contributing questionnaire responses, health data and wearable device readings across baseline, intervention and optional washout periods. Planned study topics include supplements, sleep and healthy aging, with findings intended for research summaries, scientific presentations or peer-reviewed publication. The model addresses a persistent gap in the supplement sector, where consumer products are rarely subjected to structured outcome tracking.
Oncologist and researcher Siddhartha Mukherjee outlines how cancer care is shifting toward earlier detection and therapies that exploit the metabolic and immune distinctiveness of malignant cells. He notes that second- and third-line therapies in certain cancers now produce genuine extensions of lifespan rather than marginal delays. For longevity, the practical leverage remains in risk reduction and detecting disease while it is still curable.
In 223,051 men from the UK Biobank, mosaic loss of chromosome Y in blood cells independently predicted incident age-related macular degeneration, with risk escalating beyond a defined threshold of clonal burden. Plasma proteomic shifts appeared up to 15 years before diagnosis, and single-cell data localized the highest Y-loss frequencies to CD16+ monocytes and choroidal macrophages displaying a pro-inflammatory phenotype. A machine learning model built on these protein signatures predicted five-year incident risk with an AUC of 0.734.
In aging mice, bone marrow fat cells secrete DPP4 and other factors that activate the cGAS–STING pathway in marrow macrophages, producing chronic inflammatory signaling that suppresses bone formation and lowers NAD⁺ in osteoblast progenitors. Silencing STING specifically in macrophages between 12 and 18 months preserved bone density and architecture, increased new bone deposition, and reduced marrow fat accumulation. The work positions innate immune sensing of displaced DNA as an upstream driver of age-related skeletal decline rather than a bystander.